Vaxart (VXRT) Competitors

Altimmune (NASDAQ:ALT) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Do institutionals and insiders hold more shares of ALT or VXRT?

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Comparatively, 2.6% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is ALT or VXRT more profitable?

Vaxart has a net margin of -431.61% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-199,076.92%	-55.81%	-50.60%
Vaxart	-431.61%	-110.46%	-62.78%

Do analysts recommend ALT or VXRT?

Altimmune presently has a consensus price target of $20.83, suggesting a potential upside of 327.79%. Vaxart has a consensus price target of $3.00, suggesting a potential upside of 669.23%. Given Vaxart's stronger consensus rating and higher possible upside, analysts plainly believe Vaxart is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, ALT or VXRT?

Altimmune has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Does the MarketBeat Community favor ALT or VXRT?

Vaxart received 250 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.62% of users gave Altimmune an outperform vote while only 65.61% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Altimmune	Outperform Votes 61 72.62%	Underperform Votes 23 27.38%
Vaxart	Outperform Votes 311 65.61%	Underperform Votes 163 34.39%

Which has better earnings and valuation, ALT or VXRT?

Vaxart has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$20K	18,752.91	-$88.45M	-$1.34	-3.63
Vaxart	$28.70M	3.10	-$82.46M	-$0.34	-1.15

Does the media refer more to ALT or VXRT?

In the previous week, Vaxart had 6 more articles in the media than Altimmune. MarketBeat recorded 8 mentions for Vaxart and 2 mentions for Altimmune. Altimmune's average media sentiment score of 0.93 beat Vaxart's score of 0.44 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxart	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vaxart beats Altimmune on 10 of the 19 factors compared between the two stocks.